Simona Colantonio, Ph.D., has an extensive background in mass spectrometry (MS) applied to biologically relevant molecules. In the early stages of her career, she worked at the Regina Elena National Cancer Institute of Rome, Italy and her studies focused on pharmacokinetics of anti-cancer drugs. Later on, she became involved in serum biomarker discovery while working as a guest researcher at SAIC-Frederick Inc. (now Leidos Biomedical Research).
She has been collaborating with the Antibody Characterization Laboratory (ACL) since 2009, when she was hired as a post-doctoral fellow. Since then, she has been able to achieve a deep knowledge of antibody/antigen interaction, and she has become familiar with the growing number of antibody characterization tools available at the ACL. She has been serving as ACL Director since September 2019.
Dr. Colantonio is passionate about rigor in biomedical research, and through her role at the ACL, she works to address the reproducibility crisis linked to poor research antibody quality. As director of scientific operations at the ACL, she leads an excellent team of experts in antibody characterization that tests hundreds of monoclonal antibodies developed through the NCI Antibody Program.
Dr. Colantonio has obtained a master’s degree in Pharmaceutical Chemistry and Technology and a Pharm. D. from la Sapienza University of Rome, Italy. From the same institution, she has received her Ph.D. in Pharmaceutical Sciences. In 2018 she accepted a position as Visiting Professor at her Alma Mater, La Sapienza University of Rome, Italy (Pharmaceutical Chemistry and Technology Department, March 27th, 2018- April 26th, 2018).
